Recombinant NDV Vector for Avian Influenza H5 Protection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current vaccines lack effectiveness in preventing avian influenza (AIV) infection, particularly due to interference from maternally-derived antibodies and the need for improved immunization strategies against highly pathogenic strains like H5N1.

Innovation Solution

Development of an engineered Newcastle Disease Virus (NDV) vector expressing avian influenza antigens, specifically the H5 subtype hemagglutinin, which is highly immunogenic and can be administered using a prime-boost protocol to enhance immune response in avians, thereby overcoming antibody interference and providing protection against AIV.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional vaccines are used to prevent avian influenza, then vaccination can be administered, but the vaccines lack effectiveness due to interference from maternally-derived antibodies

Engineering Contradiction:
Improvevaccine effectivenessVSAvoidmaternally-derived antibody interference
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention changes the viral vector parameters by using Newcastle disease virus (NDV) as a recombinant vector instead of conventional influenza vaccines. This parameter change allows the vaccine to bypass maternal antibody interference while maintaining immunogenicity, as the NDV vector expresses avian influenza antigens (H5N1, H5N6, H5N8) and can effectively stimulate immune response despite the presence of maternally-derived antibodies

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The NDV vector acts as an intermediary carrier that delivers avian influenza antigens to the host immune system. This intermediary approach allows the vaccine to overcome maternal antibody interference by using a different viral platform (NDV) that is not neutralized by anti-influenza maternal antibodies, while still presenting the target influenza antigens for immune recognition

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If recombinant NDV vectors are developed to express avian influenza antigens, then immune response can be enhanced, but the device complexity increases

Engineering Contradiction:
Improveimmune response effectivenessVSAvoidvaccine construction complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The NDV vector system serves multiple functions: it acts as both the delivery vehicle and the expression system for avian influenza antigens. The single recombinant NDV construct simultaneously provides viral entry, antigen expression, and immune stimulation, eliminating the need for separate components and simplifying the overall vaccine construction despite the sophisticated immunogenic response it generates

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Reliability

If prime-boost protocol is used to enhance immune response, then protection against highly pathogenic strains is improved, but the loss of time increases due to multiple administration steps

Engineering Contradiction:
Improveprotection against highly pathogenic strainsVSAvoidtime for multiple vaccinations
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The prime-boost protocol implements continuous immunization action by administering the recombinant NDV vaccine at multiple time points (day 0 and day 21). This continuous exposure to the antigen through structured booster doses maintains and enhances immune response over time, ensuring robust protection against highly pathogenic avian influenza strains while organizing the time investment in a systematic manner

Inventive Principle:
Principle #20Continuity of useful action

Data Source

PatentEP2998315B2Newcastle disease virus vectored avian vaccines
Publication Date: 2021.11.03 BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC
  • EP2998315B2 patent drawingFigure 1~1B
  • EP2998315B2 patent drawingFigure 1C
  • EP2998315B2 patent drawingFigure 2

AI summary

The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.